How Wegovy supports Weight Loss
In the ever-evolving field of weight management, Wegovy (semaglutide) has emerged as a revolutionary medication offering significant hope for those struggling with obesity. Approved by the Therapeutic Goods Administration (TGA) in Australia, Wegovy is a once-weekly injectable medication that has shown remarkable effectiveness in supporting weight loss. But how exactly does Wegovy work, and why is it considered such a powerful tool in the battle against obesity?
Understanding Wegovy: What is It?
Wegovy is the brand name for semaglutide, a medication that belongs to a class of drugs known as GLP-1 receptor agonists. Initially developed to treat type 2 diabetes under the brand name Ozempic, semaglutide’s impact on weight loss was so significant that it was rebranded as Wegovy for this specific purpose. The TGA approved Wegovy for chronic weight management in adults who are either obese (with a BMI of 30 or higher) or overweight (with a BMI of 27 or higher) and have at least one weight-related condition, such as type 2 diabetes or hypertension.
The Science Behind Wegovy
Wegovy’s effectiveness in weight loss lies in its ability to mimic the action of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 is naturally produced in the gut and plays a crucial role in regulating appetite, glucose metabolism, and insulin secretion. By acting on GLP-1 receptors in the brain, Wegovy enhances the body’s natural response to food intake, leading to several key effects that support weight loss:
- Appetite Suppression: One of the most significant ways Wegovy supports weight loss is by reducing appetite. By activating GLP-1 receptors in the hypothalamus, the part of the brain that controls hunger, Wegovy promotes a feeling of fullness (satiety) after eating. This reduces the urge to eat and helps people consume fewer calories, which is essential for weight loss.
- Slowed Gastric Emptying: Wegovy also slows down the rate at which food leaves the stomach and enters the small intestine. This delayed gastric emptying prolongs the feeling of fullness after a meal, further reducing the desire to eat between meals. This mechanism is particularly beneficial for individuals who struggle with constant hunger or overeating.
- Improved Insulin Sensitivity: Although primarily associated with weight loss, Wegovy also improves insulin sensitivity, which is particularly beneficial for individuals with type 2 diabetes. By enhancing the body’s ability to use insulin effectively, Wegovy helps regulate blood sugar levels, which can indirectly support weight loss by reducing the storage of excess glucose as fat.
Clinical Efficacy: How Effective is Wegovy?
The clinical efficacy of Wegovy has been demonstrated in several large-scale studies, most notably the STEP (Semaglutide Treatment Effect in People with Obesity) trials. These trials involved thousands of participants and provided robust evidence of Wegovy’s effectiveness in promoting significant weight loss.
In the STEP 1 trial, participants who took Wegovy lost an average of 15% of their body weight over 68 weeks, compared to just 2.4% in the placebo group . Additionally, nearly a third of participants lost 20% or more of their body weight, results that are comparable to those achieved with bariatric surgery. These outcomes highlight Wegovy as one of the most effective pharmacological treatments for obesity currently available.
Long-Term Weight Management with Wegovy
While Wegovy is highly effective in promoting initial weight loss, its long-term success depends on continued use and the incorporation of healthy lifestyle changes. Weight loss with Wegovy is most sustainable when combined with a reduced-calorie diet and regular physical activity. It is important to recognise that, like many weight loss interventions, discontinuing Wegovy may lead to weight regain. Therefore, Wegovy should be viewed as part of a comprehensive weight management strategy rather than a standalone solution.
The Role of Diet and Exercise
To maximise the benefits of Wegovy, it’s crucial to follow a balanced diet and maintain a regular exercise routine. A high-protein, low-carbohydrate diet can complement Wegovy’s appetite-suppressing effects, helping to maintain muscle mass while promoting fat loss. Regular physical activity, such as aerobic exercise and strength training, enhances weight loss by increasing calorie expenditure and improving overall fitness.
Potential Side Effects and Considerations
Like all medications, Wegovy comes with potential side effects, the most common of which are gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. These side effects are usually mild to moderate and tend to diminish as the body adjusts to the medication. It’s important for individuals considering Wegovy to discuss these potential side effects with their healthcare provider and to weigh the benefits against the risks.
Additionally, Wegovy is not suitable for everyone. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). It is also not recommended for use during pregnancy or breastfeeding. Healthcare providers will carefully evaluate each patient’s medical history to determine if Wegovy is the right choice.
For those considering Wegovy, it’s essential to consult with a healthcare provider to determine if it’s the right option and to receive guidance on how to integrate it into a comprehensive weight loss strategy. With the right approach, Wegovy can help individuals achieve their weight loss goals and improve their overall health and well-being.
References:
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.
- Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.
- Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C, Gu M. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022 Sep 14;13:935823. doi: 10.3389/fphar.2022.935823. PMID: 36188627; PMCID: PMC9515581.
- Therapeutic Goods Administration (TGA). New semaglutide product becomes available for chronic weight management. Medicine Shortage Alerts. 2023 Jul 28. Available from: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/new-semaglutide-product-becomes-available
To provide you with the best experience with Be Fit Food, we have ensured a range of documents are available to you including: Incident Management Policy, Complaints Management Policy and Complaints Management Form. If you need assistance with any of these documents, please contact our Customer Service team on 1300 263 257.